CancerApr 14, 2026
About 15% of men with a PSA level under 4.0 ng/mL, the traditional "normal" cutoff, have prostate cancer on biopsy. That single finding upended decades of assumptions about what a prostate specific antigen test can and can't tell you.
PSA is one of the most debated blood tests in medicine. Two enormous randomized trials gave seemingly opposite answers about whether screening saves lives. Guidelines have swung from recommending routine testing to advising against it, and back to something in between.
The confusion is understandable. But the research, once you piece it together, tells a more coherent story than the headlines suggest.
CancerApr 14, 2026
Burping, even frequent burping, does not show up as a warning sign for any of the major gastrointestinal cancers. Across research on esophageal, stomach, colorectal, liver, pancreatic, and biliary tract cancers, isolated burping simply isn't on the list of red-flag symptoms. The things that do signal potential cancer look very different.
That said, the reason this question deserves a real answer is that common GI cancers are often silent in their early stages, and when symptoms finally appear, they tend to be nonspecific. So understanding what actually warrants concern, and what doesn't, matters.
Lung CancerApr 14, 2026
People eating the most ultra-processed food face roughly 40% higher lung cancer risk compared to those eating the least. That finding comes from a large US clinical trial and held for both non-small cell and small cell lung cancer, the two major types. Smoking is still the overwhelming driver of lung cancer, but the accumulating evidence suggests your grocery cart matters too.
The research is all observational, meaning it can't prove cause and effect on its own. But the signal keeps showing up across different populations, different study designs, and different ways of measuring diet. And for processed meat specifically, genetic analysis is starting to support a causal connection.
CancerApr 14, 2026
Megestrol acetate can make you hungrier and help you gain a little weight. But across large systematic reviews, it has never been shown to help people live longer. That tension sits at the heart of every decision to prescribe this drug: it treats a symptom (wasting, lost appetite) while carrying real risks to your endocrine system, your blood vessels, and your metabolism. Whether that tradeoff makes sense depends entirely on what problem you're trying to solve.
Megestrol acetate is a synthetic progestin, meaning it mimics progesterone. It was originally developed as a hormonal cancer treatment and is still used that way. But its most common role today is as an appetite stimulant for people dealing with the severe weight loss and appetite collapse that come with cancer, AIDS, and other serious illnesses.
CancerApr 14, 2026
A single blood draw that detected cancer signals across more than 50 tumor types with a false positive rate under 1% sounds like it shouldn't exist yet, but a clinical validation study of over 4,000 participants showed exactly that. The Galleri test, developed by GRAIL, uses DNA methylation patterns in cell-free DNA to find cancer signals that standard screening was never designed to catch.
It's not a replacement for mammograms or colonoscopies. It's aimed at the cancers that have no screening test at all, the ones that tend to show up late and kill quickly.
So what does the science actually support, and where does the test fall short?
CancerApr 14, 2026
For decades, scientists have dreamed of a future where we could outwit cancer not by poisoning or carving it out, but by rewriting the genetic script it follows. That future is no longer science fiction. Gene therapy, which involves delivering carefully selected genetic material to counteract or kill cancer cells, is now a regular fixture in labs and clinical trials. But a new, more ambitious question is emerging: could gene therapy not just treat cancer, but help us live longer, healthier lives by preventing it in the first place?
In other words, how close are we to making gene therapy a safe and reliable tool for extending our healthspan—the portion of life spent in good health, free from chronic disease? The answer, like much of biology, is layered. There is real promise. However, these are accompanied by frustrating roadblocks and safety concerns that must be overcome before gene therapy makes the leap from treatment to prevention.
Prostate CancerApr 14, 2026
Eligard, an injectable form of leuprolide acetate, pushes testosterone down to castrate levels in the vast majority of men with prostate cancer. But "vast majority" ranges from 94% to 98% with shorter dosing intervals, dropping to roughly 88–90% with the longest option. That gap is worth understanding if you or someone you care about is choosing between a shot every month versus every six months.
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
Vitamin B12Apr 14, 2026
Vitamin B12 is an essential nutrient responsible for maintaining healthy nerve function, producing red blood cells, and supporting DNA synthesis. When the body lacks sufficient B12, a variety of symptoms can appear, including fatigue, cognitive changes, anemia, and neurological issues. These symptoms are typically attributed to nutritional causes or absorption problems. However, research has increasingly identified links between vitamin B12 deficiency and certain cancers, raising important questions about whether such a deficiency could sometimes be a sign of an undiagnosed malignancy.
Skin HealthApr 14, 2026
The nose is the single most common site on the face for non-melanoma skin cancer. It protrudes, it catches sun year-round, and its complex anatomy makes both removal and repair a challenge. But the research is clear on what determines whether nasal skin cancer comes back: clean surgical margins. When surgeons achieve clear margins, recurrence sits around 6%. With positive (incomplete) margins, it climbs to roughly 24%.
That fourfold gap makes the surgical approach one of the most consequential decisions in treatment, sometimes more so than the specific type of cancer itself.
MetforminApr 14, 2026
Roughly 1 in 5 metformin products tested in large international surveys contained a probable carcinogen above safety limits. That sounds alarming, and it should be taken seriously. But here's the tension: the other 80% of tested batches met quality and safety standards, no adverse events have been definitively linked to the contaminated products, and abruptly stopping metformin creates its own set of risks for people managing diabetes. The real question isn't whether the recalls were justified (they were), but what you should actually do about it.
Between 2020 and 2022, over 281 extended-release metformin products were recalled in the US alone. The contaminant at the center of all of this is NDMA (N-nitrosodimethylamine), a substance classified as a probable carcinogen. Regulators worldwide set a strict daily limit of 96 nanograms, and a meaningful minority of products exceeded it.
CancerApr 14, 2026
CA 19-9 is the most validated blood marker for pancreatic cancer, yet it catches only about 72–80% of symptomatic cases and flags plenty of people who don't have cancer at all. It's a genuinely useful tool in the right context, but it's also widely misunderstood. If your doctor ordered this test, or if a result came back high (or suspiciously normal), understanding what CA 19-9 can and can't tell you matters more than the number on the page.
Thyroid HealthApr 14, 2026
Nanoparticles are being engineered to fight thyroid cancer and simultaneously accumulating in thyroid tissue where they disrupt hormones. This isn't a conflict between two separate fields. It's the same class of materials producing both results depending on context, dose, and design.
The important caveat up front: nearly all of this evidence comes from animal models, cell studies, or early preclinical work. No nanoparticle-based thyroid cancer therapy is in routine human use yet. But the dual nature of NP thyroid interactions, therapeutic potential on one side, endocrine disruption on the other, is worth understanding if you follow thyroid health or cancer research.
ImagingApr 14, 2026
A CT scan gives your doctor a detailed map of your body's structures. A PET scan reveals which tissues are metabolically active, essentially showing what's "on" and what's "off." That distinction matters more than most people realize, because a lymph node that looks normal on CT might be lighting up with cancer activity on PET, and a mass that looks suspicious on CT might turn out to be harmless inflammation on PET. These two technologies answer fundamentally different questions, and knowing which question needs answering is the whole game.
When doctors combine both into a single PET/CT scan, they get anatomy and biology in one image. For many cancers, that combination outperforms CT alone for staging and detecting spread, often changing the entire treatment plan. But PET/CT isn't always the better choice. It costs more, delivers more radiation, and in some situations, a standard CT does the job just fine.
Blood TestsApr 14, 2026
A high albumin-to-globulin (A/G) ratio is one of those lab results that tends to cause worry for no reason. Across a wide range of conditions, from stroke to cancer to heart disease, a higher A/G ratio consistently tracks with better outcomes, not worse ones. The research is surprisingly clear on this: if your A/G ratio is going to lean in one direction, high is almost always preferable to low.
That said, "high" is relative. The clinical context, your other lab values, and just how high we're talking about all matter. There is a narrow window where a very elevated A/G ratio could signal something worth investigating, but the threshold for concern is well above what most people see on their results.
CancerApr 14, 2026
Most people learn to watch for dark, irregularly shaped moles. Amelanotic melanoma skips that playbook entirely. It shows up pink, red, or skin-colored, carrying little to no visible pigment. That disguise is the core problem: clinicians misdiagnose it anywhere from 25% to 89% of the time, and lesions often sit on the skin for more than a year before anyone identifies them correctly.
The result is predictable and grim. By the time amelanotic melanoma gets a proper diagnosis, tumors tend to be thicker, more advanced, and associated with worse survival than their pigmented counterparts. The cancer itself isn't inherently more lethal. It just gets a massive head start.
CancerApr 14, 2026
The overall five-year survival rate for liver cancer sits roughly between 10% and 20%. That sounds grim, but that single number hides enormous variation. People diagnosed early who receive curative treatment can see five-year survival rates of 50% to 80%. The stage at diagnosis, the treatment you receive, and the health of your liver all shift your personal outlook dramatically.
CancerApr 14, 2026
The scalp is one of the highest-risk locations on the body for skin cancer, yet it is also one of the least examined. Clinicians frequently skip thorough scalp checks, and patients can't easily see what's growing under their hair. That combination of biological aggressiveness and delayed detection is what makes scalp skin cancers stand apart from the same tumors elsewhere on the body.
Despite being a relatively small area, the scalp accounts for a disproportionately high share of squamous cell carcinomas and other keratinocyte cancers. Cutaneous squamous cell carcinoma (cSCC) on the scalp carries local recurrence rates of roughly 6 to 10 percent and lymph node metastasis rates around 7 to 9 percent, numbers that earn it a "high-risk" classification. Basal cell carcinoma (BCC) is still the most common malignant scalp tumor overall, followed by cSCC, with melanomas and rarer tumors also occurring in this location.
CancerApr 14, 2026
The honest answer about stage 4 lung cancer survival is that it depends enormously on specifics most people never hear about until they're sitting in an oncologist's office. Median survival still lands somewhere between 7 and 12 months for many patients treated with standard chemotherapy alone. But certain combinations of tumor biology, treatment type, and patient fitness are pushing some people well past the 5-year mark. The distance between the worst-case and best-case scenarios has never been wider.
That spread matters. It means a single "average" number is almost misleading. What actually predicts where someone falls on that spectrum is the type of lung cancer, whether it carries specific genetic mutations, how many places it has spread, overall health, and which treatments are on the table.
CancerApr 14, 2026
Most people learn to watch for the "ABCDE" signs of melanoma: Asymmetry, Border irregularity, Color variation, Diameter, and Evolution. Nodular melanoma frequently fails to trigger any of them. It can be symmetric, uniform in color, even skin-toned or pink. And that mismatch between what you were told to look for and what this cancer actually looks like helps explain a striking statistic: nodular melanoma accounts for only about 14 to 30% of melanoma cases, yet it causes roughly 40 to 45% of melanoma deaths.
The problem is not that nodular melanoma is undetectable. It is that it plays by different rules, and most people, including some clinicians, are scanning for the wrong things.
CancerApr 14, 2026
Anemia, defined as low levels of hemoglobin in the blood, is one of the most common complications seen in patients with cancer. While anemia itself can arise from many causes, including chronic disease, nutritional deficiencies, or bleeding, it is particularly prevalent in cancer patients, either as a direct effect of the malignancy or as a side effect of treatment. Understanding the types of cancer most strongly associated with low hemoglobin levels is essential, as anemia can significantly impact patient outcomes, quality of life, and survival.
